Pediatr Blood Cancer:儿童EBV相关T细胞淋巴增生性疾病的系统形式谱系

2020-07-27 MedSci原创 MedSci原创

儿童EBV相关T细胞淋巴增生性疾病(S-EBV-T-LPD)的系统形式包括三种主要形式。EBV阳性嗜血细胞淋巴组织细胞病(EBV-HLH)、系统性EBV阳性T细胞淋巴瘤(S-EBV-TCL)和系统性慢

儿童EBV相关T细胞淋巴增生性疾病(S-EBV-T-LPD)的系统形式包括三种主要形式。EBV阳性嗜血细胞淋巴组织细胞病(EBV-HLH)、系统性EBV阳性T细胞淋巴瘤(S-EBV-TCL)和系统性慢性活动性EBV感染(S-CAEBV)。这些疾病在西方国家的儿童中很少发生。在此,我们描述了8例此类实体的儿童。

从1990年到2015年,我们回顾性地确定了8例(6例临床和2例尸检)儿童S-EBV-T-LPD。记录了临床病理参数,包括组织形态学、免疫表型、EBV研究和T细胞受体基因重排研究。包括5名女性和3名男性患者,来自西班牙裔、亚裔和高加索人,年龄范围为14个月至9岁。

结果发现,发热、肝脾肿大、细胞减少、EBV血清学异常、EBV病毒载量非常高是常见表现。组织学检查结果显示,EBV+T细胞浸润,结构扭曲程度不一,细胞学不典型,从无到轻度细胞学不典型到明显的淋巴瘤和组织嗜血细胞增多。均表现为CD4+或CD8+T细胞异常,CD5、CD7和CD3暗淡或消失,流式细胞仪显示CD2和CD45明亮或免疫组化显示CD5消失。TCR基因重排研究显示所有临床病例均有单克隆重排(6/6)。治疗包括按HLH-94或HLH-2004方案进行化疗,并进行或不进行骨髓移植,结果不佳。

总之,在这项美国儿童S-EBV-T-LPD的大型儿科临床病理研究中,EBV-HLH、S-EBV-TCL和S-CAEBV表现出许多重叠特征。诊断具有挑战性,采用目前HLH导向的治疗方法,总体效果不佳。

原始出处:

Amy M CoffeyAnnisa Lewis, et al., A clinicopathologic study of the spectrum of systemic forms of EBV-associated T-cell lymphoproliferative disorders of childhood: A single tertiary care pediatric institution experience in North America. Pediatr Blood Cancer. 2019 Aug;66(8):e27798. doi: 10.1002/pbc.27798. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1757332, encodeId=c0881e5733281, content=<a href='/topic/show?id=2f354231613' target=_blank style='color:#2F92EE;'>#增生性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42316, encryptionId=2f354231613, topicName=增生性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f7c37300907, createdName=ms7514935887898259, createdTime=Sun Sep 13 23:12:10 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639540, encodeId=da4e1639540ff, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Jan 02 20:12:10 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728609, encodeId=46611e2860966, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 27 18:12:10 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480794, encodeId=73f91480e9442, content=<a href='/topic/show?id=cce3646351' target=_blank style='color:#2F92EE;'>#EBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6463, encryptionId=cce3646351, topicName=EBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1227684795, createdName=zjshifan_98647308, createdTime=Tue Jul 28 15:12:10 CST 2020, time=2020-07-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1757332, encodeId=c0881e5733281, content=<a href='/topic/show?id=2f354231613' target=_blank style='color:#2F92EE;'>#增生性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42316, encryptionId=2f354231613, topicName=增生性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f7c37300907, createdName=ms7514935887898259, createdTime=Sun Sep 13 23:12:10 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639540, encodeId=da4e1639540ff, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Jan 02 20:12:10 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728609, encodeId=46611e2860966, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 27 18:12:10 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480794, encodeId=73f91480e9442, content=<a href='/topic/show?id=cce3646351' target=_blank style='color:#2F92EE;'>#EBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6463, encryptionId=cce3646351, topicName=EBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1227684795, createdName=zjshifan_98647308, createdTime=Tue Jul 28 15:12:10 CST 2020, time=2020-07-28, status=1, ipAttribution=)]
    2021-01-02 仁医06
  3. [GetPortalCommentsPageByObjectIdResponse(id=1757332, encodeId=c0881e5733281, content=<a href='/topic/show?id=2f354231613' target=_blank style='color:#2F92EE;'>#增生性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42316, encryptionId=2f354231613, topicName=增生性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f7c37300907, createdName=ms7514935887898259, createdTime=Sun Sep 13 23:12:10 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639540, encodeId=da4e1639540ff, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Jan 02 20:12:10 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728609, encodeId=46611e2860966, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 27 18:12:10 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480794, encodeId=73f91480e9442, content=<a href='/topic/show?id=cce3646351' target=_blank style='color:#2F92EE;'>#EBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6463, encryptionId=cce3646351, topicName=EBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1227684795, createdName=zjshifan_98647308, createdTime=Tue Jul 28 15:12:10 CST 2020, time=2020-07-28, status=1, ipAttribution=)]
    2020-09-27 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1757332, encodeId=c0881e5733281, content=<a href='/topic/show?id=2f354231613' target=_blank style='color:#2F92EE;'>#增生性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42316, encryptionId=2f354231613, topicName=增生性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f7c37300907, createdName=ms7514935887898259, createdTime=Sun Sep 13 23:12:10 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639540, encodeId=da4e1639540ff, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Jan 02 20:12:10 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728609, encodeId=46611e2860966, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 27 18:12:10 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480794, encodeId=73f91480e9442, content=<a href='/topic/show?id=cce3646351' target=_blank style='color:#2F92EE;'>#EBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6463, encryptionId=cce3646351, topicName=EBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1227684795, createdName=zjshifan_98647308, createdTime=Tue Jul 28 15:12:10 CST 2020, time=2020-07-28, status=1, ipAttribution=)]

相关资讯

Blood:免疫缺陷相关的淋巴增生性疾病

免疫缺陷相关的淋巴增生性疾病(IA-LPDs)具有病理和临床异质性。在不同的临床环境下,IA-LPDs患者反复出现相似的特征。世界卫生组织(WHO)主要是根据移植后的淋巴增生疾病(PTLD)的类型对IA-LPDs进行分类,但术语与疾病定义不一致。目前,该领域缺乏标准化,采用通用的工作术语有助于更好的理解这些疾病并指导临床管理。Yasodha Natkunam等人提出一种由三部分组成的统一命名法,其